We are live on ! Find out more
Lazard Asset Management

Lazard Asset Management Portfolio holdings

AUM $60.8B
1-Year Est. Return 22.47%
This Fund
S&P 500
This Quarter Est. Return
+0.1%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$68.4B
AUM Growth
-$6.42B
Cap. Flow
-$9.95B
Cap. Flow %
-14.55%
Top 10 Hldgs %
25.74%
Holding
2,605
New
281
Increased
825
Reduced
894
Closed
234

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$433M
2
MRK icon
Merck
MRK
+$286M
3
J icon
Jacobs Solutions
J
+$265M
4
EFX icon
Equifax
EFX
+$253M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$240M

Sector Composition

Rank Sector Weight
1 Technology 26.04%
2 Financials 14.64%
3 Healthcare 12%
4 Industrials 10.54%
5 Consumer Discretionary 9.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LEG icon
1851
Leggett & Platt
LEG
$1.4B
$35K ﹤0.01%
3,730
-4,613
-55% -$55.2K
MFC icon
1852
Manulife Financial
MFC
$73.9B
$35K ﹤0.01%
+1,168
New +$36.2K
NVGS icon
1853
Navigator Holdings
NVGS
$1.27B
$35K ﹤0.01%
2,338
-147
-6% -$2.31K
WGS icon
1854
GeneDx Holdings
WGS
$2.08B
$35K ﹤0.01%
+457
New +$31.9K
LYB icon
1855
LyondellBasell Industries
LYB
$19.1B
$34K ﹤0.01%
466
+214
+85% +$18K
PAHC icon
1856
Phibro Animal Health
PAHC
$1.46B
$34K ﹤0.01%
1,647
+1,589
+2,740% +$36.8K
DAVA icon
1857
Endava
DAVA
$157M
$33K ﹤0.01%
1,088
REG icon
1858
Regency Centers
REG
$14.5B
$33K ﹤0.01%
447
+20
+5% +$1.46K
SCHL icon
1859
Scholastic
SCHL
$801M
$33K ﹤0.01%
+1,591
New +$40.4K
MGNX icon
1860
MacroGenics
MGNX
$248M
$32K ﹤0.01%
+9,869
New +$35.5K
ALEX
1861
DELISTED
Alexander & Baldwin
ALEX
$30K ﹤0.01%
1,743
-110
-6% -$2.07K
RDNT icon
1862
RadNet
RDNT
$5.27B
$30K ﹤0.01%
442
-8,086
-95% -$596K
VTRS icon
1863
Viatris
VTRS
$20.6B
$29K ﹤0.01%
2,377
+2,102
+764% +$25.8K
ALX
1864
Alexander's
ALX
$1.42B
$28K ﹤0.01%
+142
New +$31.4K
BLMN icon
1865
Bloomin' Brands
BLMN
$1.01B
$28K ﹤0.01%
2,389
GIB icon
1866
CGI
GIB
$15B
$28K ﹤0.01%
264
SHEN icon
1867
Shenandoah Telecom
SHEN
$720M
$28K ﹤0.01%
2,272
-150
-6% -$2.02K
UAL icon
1868
United Airlines
UAL
$43.1B
$28K ﹤0.01%
291
-6,535
-96% -$552K
VECO icon
1869
Veeco
VECO
$3.23B
$28K ﹤0.01%
1,046
-290
-22% -$8.42K
ESPR
1870
DELISTED
Esperion Therapeutics
ESPR
$27K ﹤0.01%
12,351
JBSS icon
1871
John B. Sanfilippo & Son
JBSS
$996M
$27K ﹤0.01%
320
-81
-20% -$7.18K
GDRX icon
1872
GoodRx Holdings
GDRX
$1.11B
$26K ﹤0.01%
5,656
-51,337
-90% -$282K
BFC icon
1873
Bank First Corp
BFC
$1.73B
$25K ﹤0.01%
+259
New +$25.6K
BR icon
1874
Broadridge
BR
$18.9B
$25K ﹤0.01%
112
+3
+3% +$672
PHIN icon
1875
Phinia Inc
PHIN
$2.8B
$25K ﹤0.01%
528
-8,392
-94% -$414K

Similar funds

Lazard Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Lazard Asset Management held 2,605 positions worth $68.4B, down 8.6% from $74.8B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Lazard Asset Management withdrew a net $9.95B in Q4 2024, closing 234 positions and reducing 894 holdings. Its most notable exit was Atlantica Sustainable Infrastructure plc Ordinary Shares, an estimated $210M position sold in full.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Lazard Asset Management opened a new position in Vaxcyte worth $39.8M.

  • Lazard Asset Management's largest Q4 2024 buy was Vaxcyte: 486,764 shares worth $39.8M.
  • Lazard Asset Management added most to Eli Lilly in Q4 2024, an estimated $433M increase.
  • Lazard Asset Management's biggest Q4 2024 reduction was Microsoft, cutting an estimated $710M.
  • Lazard Asset Management fully exited Atlantica Sustainable Infrastructure plc Ordinary Shares in Q4 2024, selling an estimated $210M.
  • Lazard Asset Management's ten largest holdings make up 26% of its $68.4B portfolio in Q4 2024.
  • Lazard Asset Management opened 281 new positions and closed 234 in Q4 2024.
  • Lazard Asset Management's portfolio value fell 8.6% quarter-over-quarter to $68.4B.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.